Immune checkpoints including programmed cell death-ligand 1 (PD-L1), V-type immunoglobulin domain-containing suppressor (VISTA), and B7-H4 have been demonstrated to be associated with the OSCC microenvironment, and ICB has become a novel immunotherapy to overcome cancer (16–19). Here, CD274 is linked to cancer.